Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)
EventHumanCOVID-19Vaccines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Date
- Thursday, 18 March 2021, All day
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
Event summary
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 18 March 2021.
Speakers:
- Emer Cooke (Executive Director)
- Sabine Straus (Chair of PRAC)
- Peter Arlett (Head of Data Analytics and Methods Task Force)
The press briefing will be moderated by Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.